EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Multiparametric MRI for Diagnosing Clinically Significant Portal Hypertension and Predicting Liver Decompensation

Efe Ozkaya, Octavia Bane, Enamul Bhuiyan iD, Amine Geahchan, Emre Altinmakas, Stefanie J Hectors, Paul Kennedy iD, Ghadi Abboud, Swathi Pavuluri, Richard L Ehman iD, Meng Yin, Sara Lewis und 5 weitere

Liver International · 2025

DOI: 10.1111/liv.70368 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Liver International, 2025. Verfasst von Efe Ozkaya und 16 weiteren Autor:innen. Beteiligte Einrichtung: BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Hypertension, Portal, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Clinically significant portal hypertension (CSPH; hepatic venous pressure gradient (HVPG) ≥ 10 mmHg) is a severe complication of chronic liver disease, with increased risk of variceal bleeding and liver decompensation (at HVPG ≥ 12 mmHg). This study evaluated the performance of multiparametric (mp)MRI for diagnosing CSPH and predicting liver decompensation, compared to ultrasound‐based shear wave elastography (SWE) and blood tests.

Methods

In this prospective single‐centre study (2018–2022), 59 patients (M 30, mean age 52.7 years) underwent mpMRI and HVPG measurement, with an average interval of 32 ± 31 days. The mpMRI protocol included 2D/3D MR elastography (MRE), T 1 /proprietary iron‐compensated T 1 (cT 1 )/T 1ρ mapping, gadoxetate‐enhanced dynamic contrast‐enhanced MRI (DCE‐MRI) of the liver and spleen, SWE and blood tests. Statistical analyses included Mann–Whitney U tests, ROC analysis, logistic regression and Cox proportional hazards models.

Results

CSPH was present in 13 patients (22%). Several MRI parameters showed high diagnostic performance for CSPH (AUC ≥ 0.8), with spleen stiffness‐2D MRE (AUC 0.88, 95% confidence interval (CI) 0.78–0.98) and liver uptake on DCE‐MRI (AUC 0.83, 95% CI 0.70–0.96) performing best, while SWE had AUCs of 0.63 (95% CI 0.45–0.81) for liver and 0.67 (95% CI 0.44–0.89) for spleen. Combining spleen stiffness‐2D MRE and liver uptake achieved an AUC of 0.93 (95% CI 0.86–1.00) for diagnosing CSPH. For predicting decompensation, spleen stiffness‐3D MRE and liver uptake rate had AUCs of 0.83 (95% CI 0.68–0.99) and 0.83 (95% CI 0.70–0.95), respectively, outperforming SWE.

Conclusions

Spleen stiffness measured with MRE combined with gadoxetate liver uptake (measured with DCE‐MRI) can diagnose CSPH and predict liver decompensation, with superior performance compared to SWE. Trial Registration ClinicalTrials.gov identifier: NCT03436550

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalMultiparametric Magnetic Resonance ImagingAdultAgedFemaleHumansMaleMiddle AgedContrast MediaElasticity Imaging TechniquesLiverLiver CirrhosisPredictive Value of TestsProspective StudiesROC CurveSpleen

Stichwörter der Autor:innen

elastographyhypertensionliverliver failuremagnetic resonance imagingportalspleen

Substanzen

Contrast Media

Autor:innen und Institutionen

  • BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Liver Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • The Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Enamul Bhuiyan, Paul Kennedy, Richard L Ehman

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Ozkaya, E., Bane, O., Bhuiyan, E., Geahchan, A., Altinmakas, E., Hectors, S. J., Kennedy, P., Abboud, G., Pavuluri, S., Ehman, R. L., Yin, M., Lewis, S., Bansal, M. B., Fischman, A., Thung, S., Schiano, T. D., & Taouli, B. (2025). Multiparametric MRI for Diagnosing Clinically Significant Portal Hypertension and Predicting Liver Decompensation. Liver International. https://doi.org/10.1111/liv.70368

Vancouver

Ozkaya E, Bane O, Bhuiyan E, Geahchan A, Altinmakas E, Hectors SJ, et al. Multiparametric MRI for Diagnosing Clinically Significant Portal Hypertension and Predicting Liver Decompensation. Liver International. 2025. doi:10.1111/liv.70368

BibTeX
@article{Ozkaya2025,
  author = {Ozkaya, Efe and Bane, Octavia and Bhuiyan, Enamul and Geahchan, Amine and Altinmakas, Emre and Hectors, Stefanie J and Kennedy, Paul and Abboud, Ghadi and Pavuluri, Swathi and Ehman, Richard L and Yin, Meng and Lewis, Sara and Bansal, Meena B and Fischman, Aaron and Thung, Swan and Schiano, Thomas D and Taouli, Bachir},
  title = {Multiparametric MRI for Diagnosing Clinically Significant Portal Hypertension and Predicting Liver Decompensation},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70368}
}
Kostenlos starten →